Although the functions of HDAC7 in brain are unknown and remain to be elucidated, our genetic studies lead us to conclude that inhibition of Hdac7 is not a major mediator of the beneficial effects that we obtained upon administration of SAHA to R6/2 mice and HDAC7 should not be prioritized as a therapeutic target for HD. This evidence concerns the gene HDAC7 and Huntington disease.